Curaleaf Holdingsの空売り状況は、投資家がCuraleaf Holdingsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Curaleaf Holdings (OTC:CURLF) 株価情報, 空売り情報

Curaleaf Holdings

Curaleaf is headquartered in Wakefield, Massachusetts, and cultivates and sells medicinal and recreational cannabis in the US. The company has operations in 17 states. Its brands include Curaleaf, Select, and Grassroots. The company has made acquisitions that give it exposure to the growing European market, a unique feature among US multistate operators.

Cannabis

Earnings

News

Retail Sales

Markets

AAWH

AYRWF

CRLBF

CSE:TRUL

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

GTBIF

TCNNF

TRUL

VRNOF

2024年第2四半期の大部分の大麻企業の財務業績が出揃い、その結果から興味深いトレンドが浮かび上がってきた。その1つが、米国のマルチステート・オペレーター（MSO）が供給チェーンにおけるコストと効率を改善しているという点だ。

大麻関連企業の業績　供給チェーンにおけるコストと効率が改善

Analyst Color

Penny Stocks

Guidance

Emerging Markets

Small Cap

Analyst Ratings

Trading Ideas

CCHWF

令は効率的な運営者の市場占有率の増加と持続可能なプラットフォーム構築を輝かせるだろう。第２四半期の収益を見越して、Zuanic &amp; Associatesのシニアアナリスト、Pablo Zuanic氏は、大麻市場傾向について概要を提供した。

大麻ブームか不況か　正念場の大麻市場

Government

Regulations

Politics

General

CNBS

JUSHI HLDGS INC CL B by Jushi Holdings Inc.

JUSHF

TILT

ペンシルベニア州が最近承認した予算には、大麻企業であるJushi Holdings（OTC：JUSHF）およびTILT Holdings（OTC：TILT）のような企業にとって大きな打撃を与える、大麻の娯楽利用の合法化が除外されています。

ペンシルベニア州　大麻の娯楽利用合法化に制限掲示へ

Curaleaf Holdings Inc

Morgan Stanley analyst James Faucette upgrades Evertec (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVTC#NYSE">EVTC</a>) from Underweight to Equal-Weight and raises the price target from $33 to $35.

Upgrades

Price Target

EVTC

Morgan Stanley Upgrades Evertec to Equal-Weight, Raises Price Target to $35

Morgan Stanley analyst Brian Wilczynski initiates coverage on UMB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UMBF#NASDAQ">UMBF</a>) with a Overweight rating and announces Price Target of $156.

Initiation

UMBF

Morgan Stanley Initiates Coverage On UMB Financial with Overweight Rating, Announces Price Target of $156

Needham analyst Quinn Bolton maintains NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) with a Buy and raises the price target from $145 to $160.

NVDA

Needham Maintains Buy on NVIDIA, Raises Price Target to $160

Morgan Stanley analyst Judah Frommer initiates coverage on 4D Molecular Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDMT#NASDAQ">FDMT</a>) with a Underweight rating and announces Price Target of $8.

FDMT

Morgan Stanley Initiates Coverage On 4D Molecular Therapeutics with Underweight Rating, Announces Price Target of $8

Morgan Stanley analyst Judah Frommer initiates coverage on Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Equal-Weight rating and announces Price Target of $31.

APLS

Morgan Stanley Initiates Coverage On Apellis Pharmaceuticals with Equal-Weight Rating, Announces Price Target of $31

Quantum-Si Provides Update On Innovation Roadmap & New Development Partnerships; Announces Next-Generation Platinum System, The Platinum Pro, Scheduled To Launch In H1 Of 2025

SCVL

Shoe Carnival Lowers FY24 Net Sales Outlook: Sees Revenues Of $1.20B-$1.23B Vs $1.23B Estimate (Prior View:  $1.23B-$1.25B); Company Reiterates FY24 Adjusted EPS Outlook Of $2.60-$2.75 Vs. $2.63 Estimate

With more than a week of deals planned across the entire assortment, Target will offer some of its lowest prices of the season on thousands of items, including up to 50% off tech, apparel, video games, board games, small appliances, luggage, holiday trees and other must-have items for gifting and gathering.

Target Reveals Its Lineup Of Black Friday Deals Available Now Through Nov. 30 Online And In Its Stores

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintains Quantum-Si (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) with a Buy and raises the price target from $4 to $5.5.

HC Wainwright & Co. Maintains Buy on Quantum-Si, Raises Price Target to $5.5

This collaboration aims to accelerate the development of advanced ceramic-based microspheres, a groundbreaking advancement in radiotherapeutic applications.
The partnership will see SINTX leverage its expertise in ceramic manufacturing to support NED medical's pre-clinical testing needs and perform the necessary process validation and verification activities to transition the microsphere process from the R&amp;D scale to pilot production.

SINT

SINTX  Signs Joint Development Agreement With NED Medical To Develop Next Generation Radiotherapeutic Solutions That May Have Transformative Impact On Cancer Treatment

Shoe Carnival (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCVL#NASDAQ">SCVL</a>) reported quarterly earnings of $0.71 per share which beat the analyst consensus estimate of $0.67 by 5.97 percent. The company reported quarterly sales of $306.885 million which missed the analyst consensus estimate of $316.950 million by 3.18 percent. This is a 4.07 percent decrease over sales of $319.914 million the same period last year.

Earnings Beats

Earnings Misses

Shoe Carnival Q3 2024 Adj. EPS $0.71 Beats $0.67 Estimate, Sales $306.885M Miss $316.950M Estimate

GEHC

GE HealthCare Sets Medium-Term 2026-2028 Targets: Organic Revenue Growth Mid-Single Digit (4% - 6%), Adjusted EPS Growth High-Single Digit To Low-Double Digit

Keefe, Bruyette &amp; Woods analyst Damon Delmonte initiates coverage on Northeast Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBN#NASDAQ">NBN</a>) with a Market Perform rating and announces Price Target of $102.

Keefe, Bruyette & Woods Initiates Coverage On Northeast Bank with Market Perform Rating, Announces Price Target of $102

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Biomea Fusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) with a Buy and maintains $40 price target.

Reiteration

BMEA

HC Wainwright & Co. Reiterates Buy on Biomea Fusion, Maintains $40 Price Target

GE HealthCare Reiterates 2024 Outlook For Organic Revenue Growth Trending Toward Lower End Of 1% - 2% Range; Continues To See Adjusted EPS $4.25 - $4.35 (Est $4.29)

Contracts

Media

Mega Matrix Signed A Memorandum Of Understanding With 9Yards Cinema Production To Jointly Establish An Investment Fund Focused On The Development Of Global Short Drama And Pan-entertainment Sector

Goldman Sachs analyst Catherine O'Brien reinstates AerCap Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AER#NYSE">AER</a>) with a Buy and announces $119 price target.

Goldman Sachs Reinstates Buy on AerCap Holdings, Announces $119 Price Target

HC Wainwright &amp; Co. analyst Kevin Dede reiterates Canaan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAN#NASDAQ">CAN</a>) with a Buy and maintains $3 price target.

HC Wainwright & Co. Reiterates Buy on Canaan, Maintains $3 Price Target

<a href="https://www.bloomberg.com/news/articles/2024-11-21/uber-said-to-be-in-talks-to-invest-in-us-ipo-of-china-s-pony-ai" title="https://www.bloomberg.com/news/articles/2024-11-21/uber-said-to-be-in-talks-to-invest-in-us-ipo-of-china-s-pony-ai">https://www.bloomberg.com/news/articles/2024-11-21/uber-said-to-be-in-talks-to-invest-in-us-ipo-of-china-s-pony-ai</a>

IPOs

UBER

Bloomberg Reported Earlier, Uber Said To Be In Talks To Invest In US IPO Of China's Pony AI

The dividend will be payable on February 14, 2025 to all shareholders of record as of January 14, 2025.

Dividends

GE HealthCare Boosts Q4 Cash Dividend By 17% From $0.03 To $0.035 Per Share

Curaleaf Holdings, Inc. (CURLF) Q3 2024 Earnings Call Transcript

Curaleaf Holdings (OTC) ( ($CURLF) ) has released its Q3 earnings. Here is a breakdown of the information Curaleaf Holdings (OTC) presented to its ...

Curaleaf Holdings Reports Q3 2024 Results

Canaccord analyst Matt Bottomley lowered the firm's price target on Curaleaf (CURLF) to C$7.25 from C$8.50 and keeps a Buy rating on the shares. Pu...

Curaleaf price target lowered to C$7.25 from C$8.50 at Canaccord

Curaleaf Holdings, Inc. reported its financial and operating results for the third quarter.

Curaleaf Q3 Report: 3% Increase In EBITDA And 9% Decrease In Net Loss

Roth MKM lowered the firm's price target on Curaleaf (CURLF) to $5 from $7 but keeps a Buy rating on the shares. The company reported a modest decr...

Curaleaf price target lowered to $5 from $7 at Roth MKM

In a report released today, William Kirk from Roth MKM maintained a Buy rating on Curaleaf Holdings (CURLF – Research Report), with a price target ...

Curaleaf Holdings (CURLF) Receives a Buy from Roth MKM

Curaleaf Holdings (TSE:CURA) has released an update. Curaleaf Holdings has secured a $40 million revolving credit facility from a major commercial ...

Comments

Curaleaf Holdings

空売り

Curaleaf Holdings (OTC:CURLF) 株価情報, 空売り情報

ニュース

パートナーシップ

ベンジンガ・グローバル